Study of Sunitinib in Subjects With High Risk Renal Cell Carcinoma
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This study is designed to explore the molecular modulatory effect of Sunitinib when given in
a neoadjuvant setting prior to radical or partial nephrectomy. The study will evaluate
aforementioned outcomes in 30 patients at a dose of 50mg/day for 4 weeks followed by surgery
2-4 weeks following the last dose.